Open Access

REVIEW

Unraveling the RAGE axis in pulmonary disorders: Mechanisms and therapeutical potential

by SHUOCHEN PANG¹, TAO JIA^1,*, ZIFENG YANG^2,*

1 Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China
2 National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China

* Corresponding Authors: TAO JIA. Email: ; ZIFENG YANG. Email:

BIOCELL 2024, 48(12), 1721-1734. https://doi.org/10.32604/biocell.2024.055753

Received 06 July 2024; Accepted 12 September 2024; Issue published 30 December 2024

Abstract

The Receptor for Advanced Glycation End Products (RAGE) is a multiligand receptor of the immunoglobulin superfamily, notably highly expressed in the lungs. Its interaction with a variety of ligands, including advanced glycation end products (AGEs), S100 proteins, and high mobility group box 1 (HMGB1), activates multiple signaling pathways that are pivotal in the pathogenesis of numerous pulmonary diseases and comorbidities. However, comprehensive reviews on the role of ligands-RAGE signaling in specific lung diseases are rare. This review aims to elucidate the mechanisms by which RAGE-mediated signaling pathways either provide protective or pathogenic effects in pulmonary diseases, focusing on its key regulatory roles in asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), pulmonary fibrosis (PF), Lung Cancer and COVID-19 Pneumonia, as well as to discuss its therapeutic potential in the specific context of lung diseases.

---

Keywords

---